Clinical trial · Observational
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
NCT03297125CI-TRIAL-00119884active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Advanced MRI. | Device | — | UNRESOLVED |
| Standard Magnetic Resonance Imaging (MRI) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Eligible Subjects
- description
- All enrolled subjects undergoing Optune therapy.
- interventionNames
- Device: Standard Magnetic Resonance Imaging (MRI)
- Device: Advanced MRI.
Primary outcomes (2)
- measure
- Overall survival.
- timeFrame
- Six months.
- description
- The number of subjects alive at six months.
- measure
- Overall survival.
- timeFrame
- One year.
- description
- The number of subjects alive at one year.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed glioblastoma (GBM), World Health Organization (WHO) grade IV. Exclusion Criteria: * Optune compliance \< 75%; they would be excluded from the final analyses. * History of craniectomy or significant skull defect (contraindication to Optune). * Active implantable medical device (e.g., deep brain stimulator (DBS), spinal cord stimulator, pacemaker, defibrillator, vagus nerve stimulator, programmable shunt). * Karnofsky Performance Status (KPS) \< 60.
References
Publications (0)
Data not yet available
No reference posted for this study.